Neurokinin2-R in medial septum regulate hippocampal and amygdalar ACh release induced by intraseptal application of neurokinins A and B.
The neurokinin receptors (NK-R), NK(2)- and NK(3)-R, have been implicated in behavioral processes, but apparently in opposite ways: while NK(2)-R agonism disrupts memory and has anxiogenic-like action, NK(3) -R agonists facilitate memory and display anxiolytic-like effects. Systemic application of NK(2)-R antagonists block the release of acetylcholine (ACh) in the hippocampus, which is induced by intraseptal administration of the NK(2)-R ligand, neurokinin A (NKA). We investigated the effects of medial septal injection of NKA and a preferred ligand of NK(3)-R, neurokinin B (NKB), on the activity of cholinergic neurons of the basal forebrain and assessed the role of the medial septal NK(2)-R in the control of extracellular ACh levels in cholinergic projection areas. ACh was dialysed in the frontal cortex, amygdala and hippocampus of anesthetized animals and was analysed by HPLC-EC. ACh levels in hippocampus and amygdala, but not in frontal cortex were increased after intraseptal injection of either NKA or NKB (0.1, 1, 10 μM). Application of the nonpeptidic NK(2)-R antagonist, saredutant SR48968 (1, 10, 100 pM), followed by NKA (1 μM) or NKB (10 μM) injection into the medial septum, blocked the ACh increase in hippocampus and amygdala. These results indicate that medial septal NK(2)-R have an important role in mediating ACh release, for one, via the septal-hippocampal cholinergic projection and, secondly, via direct or indirect route to the amygdala, but not frontal cortex. They also support the hypothesis that hippocampal cholinergic neurotransmission controls amygdala function suggesting that this interaction is regulated via NK(2)-R in the medial septum.
Schäble
Sandra
S
Center for Behavioral Neuroscience, Institute of Experimental Psychology, University of Düsseldorf, Universitätsstr. 1, 40225 Düsseldorf, Germany.
Huston
Joseph P
JP
Silva
Maria A de Souza
MA
D000109:Acetylcholine / Q000378:metabolism*; D000679:Amygdala / Q000378:metabolism*; D000704:Analysis of Variance; D000818:Animals; D001549:Benzamides / Q000494:pharmacology; D059329:Cholinergic Neurons / Q000187:drug effects / Q000378:metabolism; D005625:Frontal Lobe / Q000378:metabolism; D006624:Hippocampus / Q000378:metabolism*; D008297:Male; D008568:Memory / Q000187:drug effects; D015288:Neurokinin A / Q000008:administration & dosage / Q000378:metabolism*; D015287:Neurokinin B / Q000008:administration & dosage / Q000378:metabolism*; D010880:Piperidines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D018041:Receptors, Neurokinin-2 / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism*; D018042:Receptors, Neurokinin-3 / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism; D012686:Septal Nuclei / Q000378:metabolism; D020665:Septum of Brain / Q000378:metabolism
D001549:Benzamides; D010880:Piperidines; D018041:Receptors, Neurokinin-2; D018042:Receptors, Neurokinin-3; C073839:SR 48968; D015288:Neurokinin A; D015287:Neurokinin B; D000109:Acetylcholine